Acquisitive Valeant Sheds Staff As It Closes Bausch & Lomb Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The fast-growing, Canadian specialty pharma will shed thousands of jobs as it absorbs Bausch & Lomb, as part of an endeavor to save $800 million. CEO Mike Pearson’s note to employees describes a new organizational philosophy, with restructured management and business units.
You may also be interested in...
Valeant’s One-Two Punch Sends Allergan Ducking And Weaving; Who’s Next In The Ring?
Valeant’s partnership with activist investor William Ackman to acquire Allergan for around $46 billion would be Valeant’s largest acquisition but sets the stage for a protracted fight.
Valeant’s One-Two Punch Sends Allergan Ducking And Weaving; Who’s Next In The Ring?
Valeant’s partnership with activist investor William Ackman to acquire Allergan for around $46 billion would be Valeant’s largest acquisition but sets the stage for a protracted fight.
Valeant’s Expansion Ambitions Leads To Allergan’s Door
Potential $50 billion deal would buttress Valeant as a top ophthalmology and dermatology drug marketer.